A Forecast for Pharma Dividend Growth

The healthcare sector, a big overweight in the portfolios we manage, probably needs to take a breather, having outperformed the galaxy in the first part of 2013. But the secular trend in demand for drugs and care looks to be a one-way trade when viewed through the prism of developed-world demography and the rapid adoption of modern medicine in the emerging nations.

And so from that standpoint, we are willing to ride out shorter-term periods of underperformance (should they arise) so as to capture the bigger rewards of the future.

There’s a great piece at Markit by Simon Colvin this week that talks about this secular story and includes the following forecast for the pharma sector’s dividend growth:

One side effect of the guaranteed new term revenue from drug development and marketing has been the profits generated from the temporary monopolies afforded by patent protection.

While controversial, these high profits have enabled pharma firms to generate healthy dividends over the year, which are forecast to growth this fiscal year according to Markit Dividend.

Companies within the Stoxx 600 and S&P 500 pharmaceutical indices are set to raise payments by an average of 8% this fiscal year (with Abbott removed from the universe).

Only five firms are forecasted to hold payments compared to 16 which are forecasted to boost per share payment.

Overall the 23 Pharma firms in the two indexes are expected to yield an average of 2.8% in the following year.

The only firm forecast to cut its payment is Abbott Labs although this is driven by its spinoff of AbbVie. Markit is expecting the spun off company to pay $1.62 in the coming fiscal year, yielding a healthy 3.6% in the coming 12 months.

Pharma Divi1

We’re playing the trend via individual equities and a pair of ETFs. This is a great reference regardless of how your portfolio is constructed.


A long term prescription (Markit)

This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.

The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.

References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.

Wealthcast Media, an affiliate of Ritholtz Wealth Management, receives payment from various entities for advertisements in affiliated podcasts, blogs and emails. Inclusion of such advertisements does not constitute or imply endorsement, sponsorship or recommendation thereof, or any affiliation therewith, by the Content Creator or by Ritholtz Wealth Management or any of its employees. Investments in securities involve the risk of loss. For additional advertisement disclaimers see here: https://www.ritholtzwealth.com/advertising-disclaimers

Please see disclosures here.

What's been said:

Discussions found on the web
  1. video transitions travel commented on Sep 15

    … [Trackback]

    […] Info on that Topic: thereformedbroker.com/2013/05/04/a-forecast-for-pharma-dividend-growth/ […]

  2. power washing austin tx commented on Oct 02

    … [Trackback]

    […] Here you can find 86305 more Info on that Topic: thereformedbroker.com/2013/05/04/a-forecast-for-pharma-dividend-growth/ […]

  3. malaysia most trusted online casino commented on Nov 20

    … [Trackback]

    […] Find More to that Topic: thereformedbroker.com/2013/05/04/a-forecast-for-pharma-dividend-growth/ […]

  4. Devops consulting companies commented on Nov 23

    … [Trackback]

    […] Read More Info here on that Topic: thereformedbroker.com/2013/05/04/a-forecast-for-pharma-dividend-growth/ […]

  5. rbc royal bank commented on Nov 27

    … [Trackback]

    […] Read More Information here to that Topic: thereformedbroker.com/2013/05/04/a-forecast-for-pharma-dividend-growth/ […]

  6. adult sex dolls commented on Dec 08

    … [Trackback]

    […] Read More Information here to that Topic: thereformedbroker.com/2013/05/04/a-forecast-for-pharma-dividend-growth/ […]

  7. 사설토토 commented on Dec 25

    … [Trackback]

    […] Here you can find 22497 more Information to that Topic: thereformedbroker.com/2013/05/04/a-forecast-for-pharma-dividend-growth/ […]

  8. tangerine banque sign in commented on Jan 17

    … [Trackback]

    […] Info to that Topic: thereformedbroker.com/2013/05/04/a-forecast-for-pharma-dividend-growth/ […]

  9. rolex replicas for sale commented on Jan 28

    … [Trackback]

    […] Read More here on that Topic: thereformedbroker.com/2013/05/04/a-forecast-for-pharma-dividend-growth/ […]